REG - Adv Medical Solutns. - Director/PDMR Shareholding

Advanced Medical SolutionsAnnouncement

08/10/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251008:nRSH6178Ca&default-theme=true

RNS Number : 6178C  Advanced Medical Solutions Grp PLC  08 October 2025

     8 October 2025

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Director/PDMR and PCA Shareholding

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that it was
notified on 7 October 2025 that on 6 October 2025 Eddie Johnson, who is a
Director and PDMR, transferred, through sale of 18,726 Ordinary Shares of 5p
held on his behalf by Computershare Investor Services Plc ("Nominee"), at a
price of 219.98p and repurchase of a total of 18,586 Ordinary Shares, by
 Individual Savings Accounts ("ISA's") held in the name of Eddie Johnson and
Jackie Johnson, wife of Eddie Johnson, at a price of 219.90p per Ordinary
Share to Eddie Johnson and 221.10p per Ordinary Share to Jackie Johnson.

 

Following these transactions, Eddie Johnson and Persons Closely Associated
with him are interested in 313,498 Shares in the Company, representing 0.14
per cent. of the issued share capital of the Company. These transactions are
part of normalised tax planning.

 

The notification below, made in accordance with the requirements of the EU
Market Abuse Regulation, provides further detail.

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name:

     (i)   Eddie Johnson

     (ii)  Jackie Johnson
 2.  Reason for the notification
 a)  Position/status:

(i)    Chief Financial Officer
     (ii)    Wife of Eddie Johnson
 b)  Initial notification/Amendment: Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name:   Advanced Medical Solutions Group plc
 b)  LEI: 213800HJP6OWOSZI1L74
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument: Ordinary Shares
     of 5p

     Identification code: GB0004536594
 b)  Nature of the transactions:

     ·        (i) Sale of 18,726 Ordinary Shares of 5p held in the name of
     the Nominee

     ·        (ii) Purchase of 9,546 Ordinary Shares of 5p into ISA's held
     in the name of Eddie Johnson

     ·        (iii) Purchase of 9,040 Ordinary Shares of 5p into ISA's held
     in the name of Jackie Johnson
 c)  Price(s) and volume(s):

Price(s)       Volume(s)
     (i)  219.98p   18,726
     (ii) 219.90p   9,546
     (iii) 221.10p  9,040
 d)  Aggregated information:

     Aggregated volume:

(i)  18,726

(ii-iii) 18,586

     Aggregated price:

(i)  219.98p
     (ii-iii) 220.48p
 e)  Date of the transaction: 06/10/2025
 f)  Place of the transaction: London Stock Exchange, AIM Market (XLON)

d)

Aggregated information:

Aggregated volume:

(i)  18,726

(ii-iii) 18,586

Aggregated price:

(i)  219.98p
(ii-iii) 220.48p

e)

Date of the transaction: 06/10/2025

f)

Place of the transaction: London Stock Exchange, AIM Market (XLON)

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc             Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications                 Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou        AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)               Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                         Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi / Yasmina Benchekroun

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

 

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®), LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G(®). AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(®) brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employee For more information, please see
www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUBDGDBGDGUI